A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea.
OBJECTIVE
This study aims to conduct an economic evaluation of oral deferasirox (DSX) compared with infusional deferoxamine (DFO) in patients with transfusional iron overload.


METHODS
Depending on the methods for measuring time-cost and convenience associated with the mode of administration, either cost-utility analysis or cost-effectiveness analysis was undertaken. The difference in compliance rate between DSX and DFO was applied.


RESULTS
Although the drug cost of DSX was US$124,070 higher than that of DFO (US$96,039 vs. US$220,199), all other costs were lower in patients with DSX than in patients with DFO. In the cost-utility analysis, DSX resulted in US$3197 savings with a gain of 2.63 quality-adjusted life-years per patient. The result of the cost-effectiveness analysis also showed that DSX dominated DFO.


CONCLUSIONS
With a considerable improvement in convenience and injection time rather than efficacy, DSX is considered as a dominant therapy for patients with iron overload.
Kim
Jinhyun
J
College of Nursing, Seoul National University, Seoul, South Korea.
Kim
Younhee
Y
D000284:Administration, Oral; D001565:Benzoates / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D000077588:Deferasirox; D003676:Deferoxamine / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D007262:Infusions, Intravenous; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000191:economics*; D019190:Iron Overload / Q000188:drug therapy* / Q000191:economics*; D008390:Markov Chains; D008875:Middle Aged; D019057:Quality-Adjusted Life Years; D056910:Republic of Korea; D014230:Triazoles / Q000008:administration & dosage / Q000191:economics*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D003676:Deferoxamine; D000077588:Deferasirox